BGF is a prominent growth capital investor operating across the United Kingdom and Ireland, providing patient funding to small and mid-sized enterprises.
The follow-on funding from BGF brings the company's total raised to £11.5m.
"This investment is a testament to the progress OSL has made since our initial collaboration with BGF. The infusion of £3.5 million is dedicated to continuing our trajectory of technological advancements and product development. Importantly, it enables us to invest in our most valuable asset—our people—creating job opportunities and reinforcing our commitment to excellence in business development."
The Cambridge-based nanomedicine developer has raised capital to expand its laboratory facilities and accelerate product development for its polyNaut technology.
"We are also proud to be working with the Cystic Fibrosis Foundation on one of our key pipeline programmes, underscoring our commitment to advancing treatments for people with cystic fibrosis and other unmet clinical needs. This fundraise marks a pivotal moment in ViaNautis’s journey and we look forward to advancing the field of gene therapy, while creating substantial value for our shareholders."
The investment from BGF will support global expansion and ongoing product development for the Manchester technology firm.
"Customer experience has become a key driver across a multitude of sectors in recent years which, in turn, has sparked a wave of digitalisation in order to meet the needs and expectations of end users."
The HVAC technology company secured backing from BGF and Par Equity to support market expansion.
The investment round was led by BGF and East Innovate to drive commercial adoption of the company simulation platform.
"Machine Discovery is pioneering the use of machine learning to reduce product development cycles in a variety of sectors."
